A Study of Flt3-Ligand Levels in Sjögrens Syndrome

Analyzes of Cerebrospinal Fluid in Autoimmune Systemic Diseases

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01470638

Enrollment

Registered

2011-11-11

Start date

2009-06-30

Completion date

2019-04-30

Last updated

2019-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sjogrens Syndrome

Keywords

Flt3-L, CSF

Brief summary

The study aims to correlate levels of Flt3-ligand in Cerebrospinal Fluid (CSF) and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome.

Detailed description

The study aims to correlate levels of Flt3-ligand in CSF and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* fulfill the ACR-criteria for primary Sjogrens syndrome, * age above 18 years old

Exclusion criteria

* other CNS-disease

Design outcomes

Primary

Measure	Time frame
Correlate levels of Flt3-ligand in Cerebrospinal Fluid (CSF) and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome	June 2009 - June 2015

Countries

Sweden

Outcome results